Reply

Affiliations

¹ Palmetto Retina Center, West Columbia, South Carolina.
² Retina-Vitreous Associates Medical Group, Beverly Hills, California.
³ Ophthalmic Consultants of Boston, Boston, Massachusetts.
⁴ Retina Consultants of Houston, The Methodist Hospital, Houston, Texas.
⁵ Wills Eye Hospital, Philadelphia, Pennsylvania.
⁶ Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
⁷ Department of Ophthalmology, The Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.

Comment

W Lloyd Clark et al. Ophthalmology. 2016 Oct.

. 2016 Oct;123(10):e60-1.

doi: 10.1016/j.ophtha.2016.03.020.

¹ Palmetto Retina Center, West Columbia, South Carolina.
² Retina-Vitreous Associates Medical Group, Beverly Hills, California.
³ Ophthalmic Consultants of Boston, Boston, Massachusetts.
⁴ Retina Consultants of Houston, The Methodist Hospital, Houston, Texas.
⁵ Wills Eye Hospital, Philadelphia, Pennsylvania.
⁶ Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
⁷ Department of Ophthalmology, The Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.

No abstract available

Comment on

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Clark WL, et al. Ophthalmology. 2016 Feb;123(2):330-336. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30. Ophthalmology. 2016. PMID: 26522708 Clinical Trial.
Re: Clark et al.: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study (Ophthalmology 2016;123:330-6).
Azad SV, Takkar B. Azad SV, et al. Ophthalmology. 2016 Oct;123(10):e60. doi: 10.1016/j.ophtha.2016.02.049. Ophthalmology. 2016. PMID: 27664916 No abstract available.